Atrial fibrillation laboratory findings
 |
Resident Survival Guide |
| File:Critical Pathways.gif |
Sinus rhythm  |
Atrial fibrillation  |
|
Atrial Fibrillation Microchapters | |
|
Special Groups | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Cardioversion | |
|
Anticoagulation | |
|
Surgery | |
|
Case Studies | |
|
Atrial fibrillation laboratory findings On the Web | |
|
Directions to Hospitals Treating Atrial fibrillation laboratory findings | |
|
Risk calculators and risk factors for Atrial fibrillation laboratory findings | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]
Overview
Many cases of AF have no definite cause, it may be the result of various other problems (blood tests of thyroid function are required, especially for a first episode of AF, when the ventricular rate is difficult to control, or when AF recurs unexpectedly after cardioversion).
Laboratory Findings
- Renal function and electrolytes are routinely performed in patients suffering from atrial fibrillation.
- Thyroid function tests : Thyroid-stimulating hormone (TSH) is commonly suppressed in hyperthyroidism and of relevance if amiodarone is administered for treatment.
- Complete blood count
- Cardiac markers : In acute-onset AF associated with chest pain, cardiac troponins or other markers of damage to the heart muscle may be ordered.
- Coagulation studies (INR/aPTT) are usually performed, as anticoagulant medication may be commenced.
- High sensitivity C-reactive protein (hs-CRP) could act as a predictive marker for cardiac related complications and death.[1][2]
References
- ↑ Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A (2012). "Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study)". Am J Cardiol. 109 (1): 95–9. doi:10.1016/j.amjcard.2011.08.010. PMC 4062871. PMID 21962993.
- ↑ Ridker PM (2001). "High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease". Circulation. 103 (13): 1813–8. doi:10.1161/01.cir.103.13.1813. PMID 11282915.